N/A N=9 Long QT Syndrome and Sleep Apnea
Long QT Syndrome · Sleep Apnea
Primary: QT Interval (Corrected) Baseline Visit — 453.4 square root of seconds — p=0.73
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=19 Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening
Prolonged QT Interval in EKG and Sudden Death
Primary: Baseline (Pre-Ibutilide) QTcI Intervals — 412; 419 ms — p=0.04
Phase 4 N=14 Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
Long QT Syndrome
Primary: Baseline (Pre-ibutilide) Individualized Rate-corrected QT Interval (QTF) — 393; 399; 399 ms — p=0.09
Phase 4 N=1 Diltiazem in Jervell and Lange-Nielsen Syndrome
Jervell and Lange Nielsen Syndrome
Primary: QT Interval — 623 ms
Phase 1 N=26 QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors
Advanced Solid Tumor
Primary: Mean Time-matched, Baseline Corrected QTcF at Any Time Point Postdosing. — 2; 11 msec
Phase 1 N=13 Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome
LQT2 Syndrome
Primary: Change From Baseline in Standard 12-Lead Electrocardiogram (ECG) Daytime QT Interval Corrected For Heart Rate Using The Fridericia Formula (QTcF) (AUC0-8)/8 at Day 3…
N/A N=35 Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
Long QT Syndrome · Cardiac Repolarization
Primary: QTc Response to Exercise on Versus Off Beta-blocker. — 320; 317; 317; 315 ms
Phase 1 N=32 Food and Insulin Effect on QT/QTC Interval of ECG
Effects of Different Meals on the QT/QTc Interval · Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use · C-Peptide Effects on the QT/QTc Interval
Primary: The Effect of Food (Fasted and Fed State) on the Degree of QT Prolongation Caused by Moxifloxacin — 14.4; 11.6 ms — p=0.05
Phase 1 N=22 Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block
Drug-induced QT Prolongation · Pharmacokinetics · Pharmacodynamics
Primary: Change in Placebo Corrected Change From Baseline QTc and J-Tpeakc Intervals on the ECG Measured in Milliseconds When Dofetilide is Administered With Mexiletine or…
Phase 1 N=22 Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects
Drug-induced Surface ECG Changes
Primary: Placebo, and Baseline-adjusted Changes in PR, QRS, J-Tpeak, Tpeak-Tend and QTc — 6.5; 2.3; 32.1; 5.1 ms — p=<0.05
Phase 4 N=27 Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
Long QT Syndrome · Abnormalities, Drug-Induced
Primary: Baseline (Pre-ibutilide) QT-F Intervals — 417; 421; 413; 414 ms — p=0.07
N/A N=90 Heart Rate Response to Regadenoson and Sudden Cardiac Death
Left Ventricular Systolic Dysfunction · Sudden Cardiac Death
Primary: Sudden Cardiac Death — 2; 6 Participants
Phase 2 N=25 Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
Long QT Syndrome
Primary: Change in QTc Duration at 2 Months — 503; 497 miliseconds — p=0.7958
N/A N=28 Ondansetron and the QT Interval In Adult Emergency Department Patients
Ondansetron
Primary: Change in QTc Interval With Ondansetron Administration — 19.7 mS
Phase 1 N=9 A Study To Assess The Effect Of Linezolid On QTc Interval
Bacterial Infections
Primary: Cohort 1: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 1; 3; 2; 0 participants
Phase 1 N=60 CiPA Phase 1 ECG Biomarker Validation Study
Drug-induced QT Prolongation · Pharmacokinetics · Pharmacodynamics
Primary: Change From Baseline J-Tpeakc With "Balanced Ion Channel" Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir) — -8.3; -7.8; -11.5; -10.9 ms
Phase 1 N=36 A TQT Study of Effect of M2951 on Cardiac Repolarization
Healthy
Primary: Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Evobrutinib — -1.62; -2.28 milliseconds
N/A N=22 QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT)
Atrial Arrhythmia · QT Interval, Variation in · Arrhythmias, Cardiac
Primary: QT Intervals During Antiarrhythmic Loading Hospitalization — 21.8 milliseconds
Phase 2 N=51 Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
Metastatic Breast Cancer
Primary: Change From Baseline in Mean Duration of the QTc Interval — 1.2; -1.0; -4.0; -0.1 milliseconds
Phase 1 N=48 Staccato Prochlorperazine Thorough QT/QTc
Cardiotoxicity
Primary: Maximum Effect of Inhaled Prochlorperazine on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo — 5.493; 5.229 milliseconds
Phase 2 N=39 Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
Solid Tumors
Primary: Change in QTcF (QT Corrected According to Fridericia's Formula) — 3.32; 1.76; 1.84; 1.32 ms (Milliseconds)
Phase 2 N=75 A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
Solid Tumor
Primary: The Difference in the Change From Baseline (Predose on Day 1) in QTc Intervals Trabectedin Relative to Placebo at 24 Hour Post Dose by Fridericia Correction — 3.6; -6.2…
Phase 1 N=70 Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults
QT Intervals Changes · QTc Intervals Changes
Primary: Placebo-corrected Change From Baseline in QT Interval Corrected for Heart Rate Based on the Fridericia Method (QTcF) After Omecamtiv Mecarbil Dosing in Part B — -2.6…
N/A N=2,348 Vest Prevention of Early Sudden Death Trial and VEST Registry
Myocardial Infarction · Ventricular Dysfunction · Sudden Death
Primary: Sudden Death Mortality — 25; 19 Participants
Phase 1 N=48 Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT)
Anesthesia; Adverse Effect · Cardiac Arrhythmia
Primary: Change-from-baseline in QTc Interval — 2.1; 5.1; -0.1; 4.1 ms — p=<0.05
Phase 1 N=60 Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers
Healthy
Primary: Mean Difference Changes From Baseline Versus Placebo in QTcNi Intervals From Time-Matched Analysis by Largest Time Point — 7.0; 13.0; 12.6 msec — p=<0.001
N/A N=31 Methadone Monitoring for Insights Into Adverse Events
Pain · Opiate Addiction
Primary: Total Methadone Peak Plasma Concentration — 107.3; 315.4; 362.2 ng/mL
N/A N=3,889 Improve Sudden Cardiac Arrest Study
Sudden Cardiac Arrest · Ventricular Arrythmia
Primary: Time to the First Occurrence of a Ventricular Arrhythmia — 32.5; 18.3 Estimated 24-Month VT-VF Pct of Patients
Phase 1 N=48 Cardiac Safety Evaluation of P03277
Healthy Volunteers
Primary: Change-from-baseline Mean Effect of P03277 on QT Interval Expressed as QTc According to Fridericia's Formula (∆QTcF) — 0.97; 5.05; 0.24; -0.11 milliseconds
Phase 4 N=50 Safety of Argatroban Infusion in Conduction Disturbances
Stable Coronary Artery Disease (CAD) · Unstable Angina (Troponin Negative)
Primary: Mean Difference in QTc Interval Between ECG-2 and ECG-1 (ITT Population) — 0.94 milliseconds